Amylyx rises after promising early-stage trial for ALS drug

Shares of drugmaker Amylyx Pharmaceuticals AMLX.O rise 1.8% to $14.75 premarket

Co says experimental drug, AMX0114, was generally well-tolerated by first group of patients in early-stage trial for amyotrophic lateral sclerosis, or ALS

ALS is a fatal condition that causes progressive muscle weakness and loss of movement, says co

Early-stage trial enrolled 12 patients, with no serious side effects linked to treatment - AMLX

Drug is injected into spinal fluid every four weeks; aims to protect nerve cells, co says

Second group enrollment to start in Canada this month and in January in the U.S. - AMLX

As of last close, stock up ~283% YTD